Last 12 months
Inside the activity.
17 purchase rows · 44 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 16 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 1 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 12 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 9, 2026 23:24 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 28,837 | $7.13 | $205,607.81 |
DisclosureSEC source: 0001231919-26-001156 · form4-09092026_110910.xml · nonDerivative · entry 3 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,885,115 F8 · shares: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 23:23 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 28,837 | $7.13 | $205,607.81 |
DisclosureSEC source: 0001231919-26-001155 · form4-09092026_110922.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,885,115 F8 · shares: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 23:24 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 192,500 | $7.41 | $1,426,425.00 |
DisclosureSEC source: 0001231919-26-001156 · form4-09092026_110910.xml · nonDerivative · entry 2 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,913,952 F5 · shares: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 23:23 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 192,500 | $7.41 | $1,426,425.00 |
DisclosureSEC source: 0001231919-26-001155 · form4-09092026_110922.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,913,952 F5 · shares: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 23:24 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 38,500 | $7.11 | $273,735.00 |
DisclosureSEC source: 0001231919-26-001156 · form4-09092026_110910.xml · nonDerivative · entry 1 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,106,452 F1 · shares: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 23:23 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 38,500 | $7.11 | $273,735.00 |
DisclosureSEC source: 0001231919-26-001155 · form4-09092026_110922.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,106,452 F1 · shares: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 23:21 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 32,263 | $7.17 | $231,325.71 |
DisclosureSEC source: 0001231919-26-001144 · form4-09032026_110942.xml · nonDerivative · entry 3 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,144,952 F8 · shares: The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 23:21 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 32,263 | $7.17 | $231,325.71 |
DisclosureSEC source: 0001231919-26-001143 · form4-09032026_110951.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,144,952 F8 · shares: The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:21 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 25,131 | $7.19 | $180,691.89 |
DisclosureSEC source: 0001231919-26-001144 · form4-09032026_110942.xml · nonDerivative · entry 2 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,177,215 F5 · shares: The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:21 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 25,131 | $7.19 | $180,691.89 |
DisclosureSEC source: 0001231919-26-001143 · form4-09032026_110951.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,177,215 F5 · shares: The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:19 UTC |
Doshi DipalDirector · CEO
|
Tax withholdingCommon Stock | 8,724 | $7.14 | $62,323.38 |
DisclosureSEC source: 0001613084-26-000004 · wk-form4_1788470363.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,290 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:18 UTC |
Dowden Nathan JPresident & COO
|
Tax withholdingCommon Stock | 2,528 | $7.14 | $18,059.78 |
DisclosureSEC source: 0001873392-26-000006 · wk-form4_1788470291.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,060 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:15 UTC |
WENTWORTH KORY JAMESChief Financial Officer
|
Tax withholdingCommon Stock | 1,733 | $7.14 | $12,380.38 |
DisclosureSEC source: 0001725663-26-000007 · wk-form4_1788470155.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,277 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:16 UTC |
Sethuraman NatarajanPresident, Research & Develop.
|
Tax withholdingCommon Stock | 2,079 | $7.14 | $14,852.17 |
DisclosureSEC source: 0001873394-26-000005 · wk-form4_1788470182.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,238 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 23:21 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 29,088 | $7.06 | $205,361.28 |
DisclosureSEC source: 0001231919-26-001144 · form4-09032026_110942.xml · nonDerivative · entry 1 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,202,346 F1 · shares: The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 23:21 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 29,088 | $7.06 | $205,361.28 |
DisclosureSEC source: 0001231919-26-001143 · form4-09032026_110951.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,202,346 F1 · shares: The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 22:25 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 44,259 | $6.99 | $309,370.41 |
DisclosureSEC source: 0001231919-26-001135 · form4-08312026_100852.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,231,434 F8 · shares: The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018. Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 22:26 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 44,259 | $6.99 | $309,370.41 |
DisclosureSEC source: 0001231919-26-001136 · form4-08312026_100804.xml · nonDerivative · entry 3 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,231,434 F8 · shares: The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 22:25 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 3,733 | $7.01 | $26,168.33 |
DisclosureSEC source: 0001231919-26-001135 · form4-08312026_100852.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,275,693 F5 · shares: The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 22:26 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 3,733 | $7.01 | $26,168.33 |
DisclosureSEC source: 0001231919-26-001136 · form4-08312026_100804.xml · nonDerivative · entry 2 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,275,693 F5 · shares: The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:25 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 38,922 | $7.20 | $280,238.40 |
DisclosureSEC source: 0001231919-26-001135 · form4-08312026_100852.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,279,426 F1 · shares: The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 22:26 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 38,922 | $7.20 | $280,238.40 |
DisclosureSEC source: 0001231919-26-001136 · form4-08312026_100804.xml · nonDerivative · entry 1 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,279,426 F1 · shares: The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 01:28 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 14,569 | $7.06 | $102,857.14 |
DisclosureSEC source: 0001231919-26-001107 · form4-08272026_010802.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,318,348 F8 · shares: The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 01:27 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 14,569 | $7.06 | $102,857.14 |
DisclosureSEC source: 0001231919-26-001106 · form4-08272026_010830.xml · nonDerivative · entry 3 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,318,348 F8 · shares: The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 01:28 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 26,522 | $7.54 | $199,975.88 |
DisclosureSEC source: 0001231919-26-001107 · form4-08272026_010802.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,332,917 F5 · shares: The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 01:27 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 26,522 | $7.54 | $199,975.88 |
DisclosureSEC source: 0001231919-26-001106 · form4-08272026_010830.xml · nonDerivative · entry 2 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,332,917 F5 · shares: The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018. Read SEC document |
| August 24, 2026 Filed Aug 27, 2026 01:28 UTC |
MPM BioVentures 2014, L.P.10% owner
EVNIN LUKE10% owner
GADICKE ANSBERT10% owner
Foley Todd10% owner
MPM BioVentures 2014 (B), L.P.10% owner
MPM BioVentures 2014 LLC10% owner
MPM BioVentures 2014 GP LLC10% owner
MPM BIOVENTURES 2018 (B), L.P.10% owner
|
SaleCommon Stock | 21,623 | $7.34 | $158,712.82 |
DisclosureSEC source: 0001231919-26-001107 · form4-08272026_010802.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,359,439 F1 · shares: The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| August 24, 2026 Filed Aug 27, 2026 01:27 UTC |
MPM BIOVENTURES 2018, L.P.10% owner
MPM BioVentures 2018 LLC10% owner
MPM BioVentures 2018 GP LLC10% owner
|
SaleCommon Stock | 21,623 | $7.34 | $158,712.82 |
DisclosureSEC source: 0001231919-26-001106 · form4-08272026_010830.xml · nonDerivative · entry 1 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,359,439 F1 · shares: The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 10, 2026 23:54 UTC |
PARMAR KUSHDirector
|
SaleCommon Stock | 92,444 | $7.00 | $647,108.00 |
DisclosureSEC source: 0001664281-26-000004 · form4-08102026_110836.xml · nonDerivative · entry 3 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures V, L.P. Disclosed balance after: 2,691,337 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.84 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2026 Filed Aug 10, 2026 23:54 UTC |
PARMAR KUSHDirector
|
SaleCommon Stock | 52,317 | $6.85 | $358,371.45 |
DisclosureSEC source: 0001664281-26-000004 · form4-08102026_110836.xml · nonDerivative · entry 2 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures V, L.P. Disclosed balance after: 2,783,781 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 07, 2026 Filed Aug 10, 2026 23:52 UTC |
5AM Ventures V, L.P.10% owner
5AM Partners V, LLC10% owner
5AM Opportunities I, L.P.10% owner
5AM Opportunities I (GP), LLC10% owner
ROCKLAGE SCOTT M10% owner
Schwab Andrew J.10% owner
|
SaleCommon Stock | 52,317 | $6.85 | $358,371.45 |
DisclosureSEC source: 0001231919-26-000854 · form4-08102026_110837.xml · nonDerivative · entry 2 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783,781 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 23:54 UTC |
PARMAR KUSHDirector
|
SaleCommon Stock | 10,494 | $7.00 | $73,458.00 |
DisclosureSEC source: 0001664281-26-000004 · form4-08102026_110836.xml · nonDerivative · entry 1 PARMAR KUSH · CIK 0001664281 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures V, L.P. Disclosed balance after: 2,836,098 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 23:52 UTC |
5AM Ventures V, L.P.10% owner
5AM Partners V, LLC10% owner
5AM Opportunities I, L.P.10% owner
5AM Opportunities I (GP), LLC10% owner
ROCKLAGE SCOTT M10% owner
Schwab Andrew J.10% owner
|
SaleCommon Stock | 10,494 | $7.00 | $73,458.00 |
DisclosureSEC source: 0001231919-26-000854 · form4-08102026_110837.xml · nonDerivative · entry 1 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,836,098 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 21:32 UTC |
5AM Ventures V, L.P.10% owner
5AM Partners V, LLC10% owner
5AM Opportunities I, L.P.10% owner
5AM Opportunities I (GP), LLC10% owner
ROCKLAGE SCOTT M10% owner
Schwab Andrew J.10% owner
|
SaleCommon Stock | 1,718 | $6.85 | $11,768.30 |
DisclosureSEC source: 0001231919-26-000822 · form4-08032026_090845.xml · nonDerivative · entry 2 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,846,592 F2 · ownership.direct: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 21:26 UTC |
PARMAR KUSHDirector · 10% owner
|
SaleCommon Stock | 1,718 | $6.85 | $11,768.30 |
DisclosureSEC source: 0001664281-26-000002 · form4-08032026_090837.xml · nonDerivative · entry 2 PARMAR KUSH · CIK 0001664281 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures V, L.P. Disclosed balance after: 2,846,592 Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 21:32 UTC |
5AM Ventures V, L.P.10% owner
5AM Partners V, LLC10% owner
5AM Opportunities I, L.P.10% owner
5AM Opportunities I (GP), LLC10% owner
ROCKLAGE SCOTT M10% owner
Schwab Andrew J.10% owner
|
SaleCommon Stock | 114,756 | $6.93 | $795,259.08 |
DisclosureSEC source: 0001231919-26-000822 · form4-08032026_090845.xml · nonDerivative · entry 1 5AM Ventures V, L.P. · CIK 0001674324 · 10% owner 5AM Partners V, LLC · CIK 0001791889 · 10% owner 5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner 5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,848,310 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 21:26 UTC |
PARMAR KUSHDirector · 10% owner
|
SaleCommon Stock | 114,756 | $6.93 | $795,259.08 |
DisclosureSEC source: 0001664281-26-000002 · form4-08032026_090837.xml · nonDerivative · entry 1 PARMAR KUSH · CIK 0001664281 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures V, L.P. Disclosed balance after: 2,848,310 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:05 UTC |
Radhakrishnan MahaDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0002013423-26-000002 · wk-form4_1781298346.xml · derivative · entry 1 Radhakrishnan Maha · CIK 0002013423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 17:16 UTC |
Chapman GinaDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000043 · wk-form4_1781298996.xml · derivative · entry 1 Chapman Gina · CIK 0001989220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 16:52 UTC |
Zeiher Bernhardt GDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000034 · wk-form4_1781297526.xml · derivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 17:17 UTC |
KIM PETER SDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000044 · wk-form4_1781299039.xml · derivative · entry 1 KIM PETER S · CIK 0001181180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:34 UTC |
PARMAR KUSHDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000047 · wk-form4_1781300088.xml · derivative · entry 1 PARMAR KUSH · CIK 0001664281 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:01 UTC |
Thistle MaryDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001689375-26-000036 · wk-form4_1781298072.xml · derivative · entry 1 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| May 20, 2026 Filed May 21, 2026 16:31 UTC |
Zeiher Bernhardt GDirector
|
PurchaseCommon Stock | 5,000 | $5.86 | $29,316.00 |
DisclosureSEC source: 0001689375-26-000030 · wk-form4_1779395488.xml · nonDerivative · entry 1 Zeiher Bernhardt G · CIK 0001971421 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:24 UTC |
Dowden Nathan JPresident & COO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · derivative · entry 3 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,831 Underlying: Common Stock · 15,000 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. F3 · derivative.exercise_date: The shares subject to this option fully vested on November 4, 2023. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:24 UTC |
Dowden Nathan JPresident & COO
|
SaleCommon Stock | 15,000 | $15.33 | $229,953.00 |
DisclosureSEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,588 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:24 UTC |
Dowden Nathan JPresident & COO
|
Exercise / conversionCommon Stock | 15,000 | $1.74 | $26,100.00 |
DisclosureSEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:25 UTC |
Sethuraman NatarajanPresident, Research & Develop.
|
SaleCommon Stock | 25,907 | $15.39 | $398,809.77 |
DisclosureSEC source: 0001873394-26-000003 · wk-form4_1777937098.xml · nonDerivative · entry 1 Sethuraman Natarajan · CIK 0001873394 · President, Research & Develop. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,317 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.6150, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:39 UTC |
WENTWORTH KORY JAMESChief Financial Officer
|
SaleCommon Stock | 2,500 | $12.95 | $32,375.00 |
DisclosureSEC source: 0001725663-26-000005 · wk-form4_1775162353.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,010 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:35 UTC |
Dowden Nathan JPresident & COO
|
SaleCommon Stock | 11,894 | $13.05 | $155,188.15 |
DisclosureSEC source: 0001873392-26-000002 · wk-form4_1773261310.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,588 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.